Ventyx Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Tang Capital Management and associated entities have reported a 0% beneficial ownership stake in Ventyx Biosciences, Inc.
Affinity Asset Advisors, LLC and Michael Cho report holding 0% of Ventyx Bioscience's common stock as of March 31, 2026.
Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G, reporting no beneficial ownership of Ventyx Biosciences, Inc. common stock as of March 31, 2026.
Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 6.23% in Ventyx Biosciences, Inc. common stock.
Morgan Stanley has filed an amended Schedule 13G, reporting its beneficial ownership in Ventyx Biosciences, Inc. has fallen below the 5% threshold.
Morgan Stanley has reported a 6.0% beneficial ownership stake in Ventyx Biosciences, Inc., holding 4,289,915 common shares as of December 31, 2025.
Affinity Asset Advisors, LLC and Michael Cho have reported a 9% beneficial ownership stake in Ventyx Bioscience, Inc. common stock.
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a beneficial ownership of 4.5% in Ventyx Biosciences, Inc., indicating a reduction below the 5% threshold.
The Vanguard Group has reported a passive ownership stake of 5.28% in Ventyx Biosciences Inc., holding 3,769,997 shares of common stock.
Point72 Asset Management, along with affiliates, reported a beneficial ownership of 8.3% in Ventyx Biosciences, Inc., holding 5,895,069 common shares as of June 30, 2025.
SCHEDULE 13G/A: BlackRock Discloses 1.9% Passive Stake in Ventyx Biosciences
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.9% passive beneficial ownership stake in Ventyx Biosciences, Inc. as of June 30, 2025.
Affinity Healthcare Fund, LP and its investment manager, Affinity Asset Advisors, LLC, have reported a 5.70% beneficial ownership stake in Ventyx Biosciences, Inc. through a Schedule 13G filing.
Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin have jointly disclosed a 2.0% beneficial ownership stake in Ventyx Biosciences, Inc. as of March 31, 2025.
Bank of America Corporation has filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership stake in Ventyx Biosciences, Inc. as of March 31, 2025.
Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a 3.63% beneficial ownership stake in Ventyx Biosciences, Inc. as of March 31, 2025.
Bank of America Corporation has filed a Schedule 13G, reporting a 6.5% beneficial ownership stake in Ventyx Biosciences, Inc., comprising 4,616,536 shares of common stock as of December 31, 2024.
SCHEDULE 13G/A: Deerfield Entities Amend Ventyx Biosciences Stake, Disclosing 0.76% Passive Ownership
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have filed an amended Schedule 13G, reporting a combined beneficial ownership of 0.76% in Ventyx Biosciences, Inc. as of December 31, 2024.
Sio Capital Management, LLC has reported a 5.72% beneficial ownership stake in Ventyx Biosciences, Inc., holding over 4 million shares as of December 31, 2024.
Point72 Asset Management, along with its affiliates Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a passive 6.2% beneficial ownership stake in Ventyx Biosciences, Inc., totaling 4,400,325 shares.